Last mentioned: Mar 24, 2026
2025 Annual Results
Fosun Pharma officially releases its full-year financial performance for 2025.
Annual Results
Official release of 2025 financial performance data to global markets.
Target Horizon
Expected period for achieving the RMB 10 billion annual profit milestone.
Global Partnership
Strategic agreement signed for the distribution of biosimilars in emerging markets.
US FDA Approval
Key biosimilar assets receive final marketing authorization for the US market.
CAR-T Milestone
Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
CAR-T Expansion
Yescarta receives expanded indication approval for second-line treatment in China.
Regional Launch
Serplulimab receives regulatory approval in additional Southeast Asian markets.
Strategic Reaffirmation
Management confirms RMB 10 billion profit target and shift to growth.
ADC Platform Milestone
First internally developed ADC candidate enters Phase II clinical trials.
De-Risking Phase
Aggressive asset disposals and debt reduction to stabilize the balance sheet.
Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.
Fosun International has reaffirmed its commitment to a RMB 10 billion annual profit target over the next three to five years, signaling a transition from risk mitigation to sustainable growth. The management's outlook emphasizes the successful navigation of cyclical volatility and the stabilization of its core business pillars.